Defining pseudoprogression in glioblastoma multiforme. Issue 10 (17th May 2013)

• Record Type: Journal Article
• Authors: Van, E.; Wozniak, A.; Geussens, Y.; Menten, J.; De, S.; Van, F.; Sciot, R.; Van, S.; Bechter, O. E.; Demaerel, P.; Wilms, G.; Clement, P. M.
• Is Part Of: European journal of neurology. Volume 20:Issue 10(2013:Oct.)
• Page Start: 1335
• Page End: 1341
• Publication Date: 2013-05-17
• Subjects: Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.12192
• Languages: English
• ISSNs: 1351-5101

Abstract

<abstract abstract-type="main" xml:lang="en" id="ene12192-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ene12192-sec-0001" sec-type="section"> <title>Background and purpose</title> <p>Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients. However, the criteria defining pseudoprogression, its incidence, the time of occurrence and its impact on therapy and outcome remain poorly defined.</p> </sec> <sec id="ene12192-sec-0002" sec-type="section"> <title>Methods</title> <p>The objective of this study is to compare two sets of criteria (liberal and stringent), defining pseudoprogression, in a cohort of patients treated before and after the introduction of RT/TMZ in the standard postoperative treatment. This retrospective review includes 136 unselected and consecutively treated patients with pathologically diagnosed GBM.</p> </sec> <sec id="ene12192-sec-0003" sec-type="section"> <title>Results</title> <p>Pseudoprogression was observed in 10 (12%) cases applying the stringent criteria, and in 18 (23%) patients when using the liberal criteria, in the cohort treated with RT/TMZ. Pseudoprogression was observed in only one patient treated with RT alone. The median time to pseudoprogression was 4 weeks after the end of RT. Patients with pseudoprogression had a median survival time of 28 months, compared with 12 months for patients without pseudoprogression.</p> </sec> <sec id="ene12192-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The incidence of pseudoprogression after RT/TMZ strongly depends on the applied criteria. However, regardless of the stringency of the criteria, the impact on survival remains the same.</p> </sec> </abstract>